文献速递肿瘤 PET/CT放射性药物与辐射防护

免疫检查点TIGIT无创可视化研究进展:一项系统综述

Advancements in non-invasive visualization of the immune checkpoint TIGIT: a systematic review.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-07-15

该系统性综述检索截至2025年2月的文献,评估靶向TIGIT的放射性示踪剂无创显像研究进展。共纳入6项研究,涉及放射性标记抗体、肽和纳米抗体用于PET和SPECT显像,在临床前模型和一项探索性临床研究中显示高特异性并可可视化TIGIT表达。作者认为这些示踪剂未来可能有助于改善患者选择和治疗监测,但需进一步研究和临床验证以优化其常规临床应用。

要点

  • 共纳入6项研究,探索靶向免疫细胞TIGIT表达的示踪剂。
  • 示踪剂包括放射性标记抗体、肽和纳米抗体,用于PET和SPECT显像。
  • 这些示踪剂在临床前模型和一项探索性临床研究中显示高特异性并可可视化TIGIT表达。

核心结论

  • 靶向TIGIT的新型放射性示踪剂在无创显像方面显示出增强个性化癌症免疫治疗的潜力。
  • TIGIT靶向显像剂可对肿瘤/肿瘤微环境中的TIGIT表达进行可视化和定量,未来可能有助于更好的患者选择和治療监测。
  • 需要进一步研究和临床验证以优化这些显像技术用于常规临床应用。

研究设计与样本

  • 系统综述,检索截至2025年2月的PubMed和Web of Science数据库。
  • 检索词包括「TIGIT imaging」「TIGIT PET」「TIGIT SPECT」和「TIGIT visualization」。
  • 纳入报告靶向TIGIT表达的免疫PET示踪剂开发、表征或应用的研究,包括临床前和临床研究。
  • 共6项研究符合纳入标准。

主要发现

  • 6项研究探索了靶向免疫细胞上TIGIT表达的示踪剂。
  • 研究聚焦于TIGIT靶向显像剂的开发,包括用于PET和SPECT显像的放射性标记抗体、肽和纳米抗体。
  • 这些示踪剂在临床前模型和一项探索性临床研究中显示高特异性,并可可视化TIGIT表达。

局限性

  • 需要进一步研究和临床验证以优化这些显像技术用于常规临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a novel immune checkpoint receptor implicated in tumor immune evasion. Non-invasive imaging of TIGIT expression holds potential for improving patient selection and monitoring in cancer immunotherapy. This systematic review aims to evaluate recent advancements in radiotracer development for non-invasive visualization of TIGIT. METHODS: A comprehensive literature search was conducted up to February 2025 using databases including PubMed and Web of Science. The search terms "TIGIT imaging", "TIGIT PET", "TIGIT SPECT", and "TIGIT visualization" were used, focusing on those reporting on the development, characterization, or application of immuno-PET tracers targeting TIGIT expression. Both preclinical and clinical studies were reviewed. RESULTS: Six studies met the inclusion criteria, exploring tracers targeting TIGIT expression on immune cells. These studies have focused on the development of TIGIT-targeted imaging agents, including radiolabeled antibodies, peptides, and nanobodies for positron emission tomography (PET) and single-photon emission tomography (SPECT) imaging. These agents demonstrated high specificity and enabled visualization of TIGIT expression in preclinical models and one exploratory clinical study. CONCLUSION: Novel radiotracers for non-invasive imaging of TIGIT show potential for enhancing personalized cancer immunotherapy. TIGIT-targeted imaging agents allow for the visualization and quantification of TIGIT expression in tumors/tumor microenvironment, which in future might contribute to better patient selection and treatment monitoring. Further research and clinical validation are necessary to optimize these imaging techniques for routine clinical application.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lütje S, Schäfer L, Altunay B, et al. Advancements in non-invasive visualization of the immune checkpoint TIGIT: a systematic review. Eur J Nucl Med Mol Imaging. 2025. PMID: 40663162. doi:10.1007/s00259-025-07439-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。